(Q34462600)

2 August 2017

0 references

Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

Li Feng

1

1 reference

2 August 2017

Jin Deng

2

1 reference

2 August 2017

Dong-Mei Huo

3

1 reference

2 August 2017

Qiao-Yuan Wu

4

1 reference

2 August 2017

Yun-Hua Liao

5

1 reference

2 August 2017

publication date

1 February 2013

1 reference

2 August 2017

1 reference

2 August 2017

volume

18

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

104-110

1 reference

Understanding lupus nephritis: diagnosis, management, and treatment options

2 August 2017

cites work

1 reference

Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups.

21 January 2018

1 reference

Update on the treatment of lupus nephritis

21 January 2018

1 reference

Treatment of severe proliferative lupus nephritis: the current state

21 January 2018

1 reference

European consensus statement on the terminology used in the management of lupus glomerulonephritis

21 January 2018

1 reference

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

21 January 2018

1 reference

Treatment of proliferative lupus nephritis: a slowly changing landscape

21 January 2018

1 reference

Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis

21 January 2018

1 reference

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

21 January 2018

1 reference

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

21 January 2018

1 reference

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis

21 January 2018

1 reference

Mycophenolate mofetil during pregnancy: some words of caution.

21 January 2018

1 reference

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

21 January 2018

1 reference

Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal

21 January 2018

1 reference

Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis

21 January 2018

1 reference

Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/NEP.12006

1 reference

2 August 2017

1 reference